Scy1-like 1 (Scyl1), a member of the Scy1-like family of catalytically inactive protein kinases, was recently identified as the gene product altered in muscle-deficient mice, which suffer from motor neuron degeneration and cerebellar atrophy. To determine the function of Scyl1, we have now used a mass spectrometry-based screen to search for Scyl1-binding partners and identified components of coatomer I (COPI) coats. The interaction was confirmed in pull-down assays, and Scyl1 co-immunoprecipitates with ␤COP from brain lysates. Interestingly, and unique for a non-transmembrane domain protein, Scyl1 binds COPI coats using a C-terminal RKLD-COO ؊ sequence, similar to the KKXX-COO ؊ COPI-binding motif found in transmembrane endoplasmic reticulum (ER) proteins. Scyl1 co-localizes with ␤COP and is localized, in an Arf1-independent manner, to the ER-Golgi intermediate compartment and the cis-Golgi, sites of COPI-mediated membrane budding. The localization and binding properties of Scyl1 strongly suggest a function in COPI transport, and inhibitory RNA-mediated knock down of the protein disrupts COPI-mediated retrograde traffic of the KDEL receptor to the ER without affecting anterograde traffic from the ER. Our data demonstrate a function for Scyl1 as an accessory factor in COPI trafficking and suggest for the first time that alterations in the COPI pathway result in neurodegenerative disease.
The murine autosomal recessive neurodegenerative disease model "muscle-deficient" (mdf) displays clinical and histological features indicative of a progressive motor neuropathy (1) . Homozygotes develop a posterior waddle at 4 -8 weeks of age followed by hind limb paralysis and forelimb weakness (1) . Skeletal muscles exhibit a neurogenic atrophy, and there is progressive neurodegeneration of lower motor neurons (1, 2) . Among the murine neuromuscular atrophies, the motor neuron degeneration in mdf is most similar to that seen in wobbler (1) . Interestingly, mdf also suffers from symptoms indicative of cerebellar involvement including gait ataxia, abnormal hind limb posture, and tremor (3) . Therefore, mdf appears to be linked to both neuromuscular atrophy and spinocerebellar ataxia and is thus an animal model for neuromuscular disease with cerebellar involvement in humans.
Most recently, null mutations in the Scy1-like 1 (Scyl1) gene were determined to be responsible for the pathology seen in the mdf mouse (3). Scyl1 was initially identified as a ubiquitously expressed member of the Scy1-like family of protein kinases (4) and is a distant homologue of Scy1-like 2/CVAK104 (coated vesicle-associated kinase of 104 kDa), which is involved in the trafficking of clathrin-coated vesicles (CCVs) 3 (5-7). Scy1-like kinases are thought to be kinase-inactive as they lack several highly conserved residues essential for catalytic activity (8, 9) . Scyl1 was indirectly implicated in clathrin-mediated endocytosis when it was identified as an in vitro binding partner for the ␣-and ␤2-ear domains of the clathrin adaptor protein-2 (AP-2) (in this study, Scyl1 was referred to as CVAK90) (10) , and when it was demonstrated to be one of 92 proteins that affect the endocytic entry of vesicular stomatitis virus in a small inhibitory RNA (siRNA)-based screen of the human "kinome" (11) . A variant of Scyl1, known as N-terminal kinase-like, was found to localize to centrosomes during mitosis and was thus argued to be involved in centrosome-related functions (12) .
Here we undertake a cell biological and biochemical characterization of Scyl1 in an attempt to better define the cellular pathway(s) in which the protein functions. Our data show that Scyl1 binds to and co-localizes with the membrane trafficking coatomer I (COPI) complex, and that this interaction is mediated predominantly through a novel dibasic motif, related to the classical KKXX-COO Ϫ motif that defines transmembrane protein interactions with COPI coats (13) (14) (15) . Our data firmly establish the localization of Scyl1 to the early secretory pathway, specifically at the endoplasmic reticulum (ER)/Golgi intermediate compartment (ERGIC) and the cis-Golgi, both of which are sites where COPI is known to function in Golgi to ER retrograde trafficking. Inhibitory RNA-mediated knockdown (KD) of Scyl1 leads to a defect in COPI-dependant trafficking of the KDEL receptor (KDELR) from the Golgi to the ER. Thus, Scyl1 functions in COPI-mediated vesicle trafficking, suggesting a link between this fundamental cellular pathway and neurodegenerative disorders.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents-An affinity-purified polyclonal antibody against the C-terminal most 28 amino acids of mouse Scyl1 (National Center for Biotechnology Information (NCBI) accession number: NP_076401) was a generous gift from Dr. Gustav Lienhard (Dartmouth Medical School) (4) . Monoclonal antibodies against GM130, the ␥-adaptin subunit of adaptor protein 1 (AP-1), the ␣-adaptin subunit of adaptor protein 2 (AP-2), and the clathrin-heavy chain were from BD Transduction Laboratories. Monoclonal antibodies against 58K/FTCD, the Na ϩ /K ϩ -ATPase, and transferrin receptor were from Sigma, Upstate Biotechnology, and Zymed Laboratories Inc., respectively. Rabbit polyclonal antibodies against GFP and mannosidase II were from Molecular Probes and Chemicon, respectively. Sheep antibody for TGN46 was from Serotec. Monoclonal antibody against ␤COP, used for immunofluorescence, was a gift from Dr. John Bergeron (McGill University) (15) , and monoclonal antibody against ␤COP used for Western blot was from Dr. Tommy Nilsson (Goteborg University) (15) or was purchased from AbCam. A monoclonal antibody against VSVG was graciously provided by Dr. Victor Hsu (Harvard Medical School). A polyclonal ␤COP antibody for immunofluorescence and immunoprecipitation was from AbCam. Antibody against NECAP 1 was described previously (16) . Peptides encoding the C terminus of Scyl1 (KKTTKGPMKLGARKLD-COO Ϫ ) and p24␣2 (QMRHLKSFFEAKKLV-COO Ϫ ) were prepared with a free carboxyl group by New England Peptide. A peptide encoding two DPW motifs from epsin (CSDPWGSD-PWG) was from the Yale Keck Biotechnology Resource Laboratory. Various cDNA constructs were prepared as described in the supplemental Experimental Procedures.
Pull-down and Co-immunoprecipitation Assays-For pulldown assays, frozen rat tissues were homogenized in buffer A (20 mM HEPES, pH 7.4, 0.83 mM benzamidine, 0.23 mM phenylmethylsulfonyl fluoride, 0.5 g/ml aprotinin, and 0.5 g/ml leupeptin) and spun at 800 ϫ g for 5 min, the supernatant was collected, and Triton X-100 was added to 1% final concentration. Following 15 min at 4°C, the extracts were spun at 116,000 ϫ g for 30 min, the supernatant was adjusted to 1 or 2 mg/ml, and NaCl was added to 50 mM final. Aliquots of 1 ml were incubated for ϳ3 h at 4°C with GST or GST-Scyl1 fusion proteins precoupled to glutathione-Sepharose beads. Beads were subsequently washed three times with ice-cold buffer A with 1% Triton X-100 and 50 mM NaCl and analyzed by SDS-PAGE. Bands specifically interacting with GST-Scyl1 fusion proteins were cut and analyzed by tandem mass spectrometry (MS) as described (17) or were processed for Western blot. For peptide competition experiments, GST fusion proteins of the C-terminal 15 amino acids of p24␣2 (QMRHLKSFFEAKKLV) or full-length Scyl1 (see supplemental Experimental Procedures) were coupled to glutathione-Sepharose and were incubated with various peptides at defined molar ratios of peptide to fusion protein prior to the addition of the tissue extracts and processing of the samples as described above. For immunoprecipitation assays, tissue extracts prepared as described above were incubated with polyclonal or monoclonal antibodies precoupled to protein A-or protein G-Sepharose, respectively, and the samples were processed as described for the pull-down assays. Immunofluorescence analysis is described in the supplemental Experimental Procedures.
Inhibitory RNA-mediated KD of Scyl1-Two siRNA sequences were used to deplete Scyl1 in HeLa cells: Scyl1-1, 5Ј-AAGAAGTGGTCAGCAGACATG-3Ј,andScyl1-2,5Ј-AAC-CTCTTCCTGGAGGAGATT-3Ј. siRNAs were ordered from Qiagen Inc. and contained two-base deoxythymidine overhangs. For transfection of siRNAs, HeLa cells were plated at 50% confluency in Dulbecco's modified Eagle's medium (Invitrogen) without antibiotics on 6-well dishes and transfected with either Scyl1-1, Scyl1-2, or a control siRNA: 5Ј-AAC-AGGATGAGTTTCTAAATT-3Ј, to a final concentration of 30 or 80 nM, using the Lipofectamine 2000 transfection reagent according to the manufacturer's instructions. siRNAs were either transfected on two consecutive days at 30 nM or transfected once at 80 nM. Fresh Dulbecco's modified Eagle's medium with antibiotics was replaced following the final transfection, and 72 h after transfection, cells were replated onto glass coverslips. Following an overnight incubation at 37°C, cells were processed for indirect immunofluorescence. For Western blots, 2 wells of a 6-well plate were harvested 96 h after transfection in Nonidet P-40 buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 0.1% Nonidet P-40 detergent, 1% glycerol, 0.83 mM benzamidine, 0.23 mM phenylmethylsulfonyl fluoride, 0.5 g/ml aprotinin and 0.5 g/ml leupeptin) and spun at 23,500 ϫ g at 4°C for 5 min, and the supernatant was collected for analysis. Equal protein levels were loaded and subjected to SDS-PAGE analysis. Alternatively, Scyl1 KD was achieved using a microRNA (miRNA) expression vector containing an oligonucleotide corresponding to Scyl1 siRNA 1. The sense oligonucleotide 5Ј-TGCTGCATGTCTGCTGACCACTTCTCGTTT-TGGCCACTGACTGACGAGAAGTGCAGCAGACATG-3Ј or the sense control oligonucleotide 5Ј-TGCTGACGTGACAC-GTTCGGAGAATTGTTTTGGCCACTGACTGACAATTCT-CCACGTGTCACGT-3Ј were annealed with their antisense partners and subcloned into the vector 6.2-GW/EmGFP-miR (Invitrogen) in which the open reading frame for EmGFP was replaced with mRFP. Cells were transfected with Lipofectamine 2000 as described above.
VSVG Anterograde Transport Assays-A VSVGts045-GFP chimera construct was transfected into cells following transfection with control or Scyl1-specific siRNA, and anterograde trafficking assays were performed essentially as described (18, 19) . Briefly, 48 h after the first detectable expression of the GFP construct, cells were switched to the restrictive temperature of 40°C, and after an overnight incubation, they were switched to media containing 150 g/ml cycloheximide to prevent new VSVGts045-GFP protein synthesis. Cells were then transferred to the permissive temperature of 32°C, and at various time points, they were fixed and processed for immunofluorescence.
VSVG-KDELR Retrograde Assays-VSVGts045-KDELR construct, a gift of Dr. Victor Hsu (Harvard Medical School), was transfected into cells 48 h following transfection of control or Scyl1-specific siRNA, and retrograde assays were performed essentially as described (20, 21) . Briefly, at 48 h following transfection of the VSVGts045-KDELR construct, cells were placed at the permissive temperature of 32°C for 1 h. Following this incubation, half of the cells were fixed and processed for immunofluorescence. The remaining cells were placed at the nonpermissive temperature of 40°C for 1 h, at which point they were fixed and processed for immunofluorescence. Alternatively, retrograde trafficking assays were performed in HeLa cells with stable expression of a VSVGts045-KDELR construct containing a D195N mutation in the KDELR portion (20) . The cells, a gift of Dr. Nelson Cole, National Institutes of Health, were transfected with control or Scyl1-specific miRNA plasmid. At 96 h after transfection, cells were fixed and processed for immunofluorescence or were placed at the non-permissive temperature of 40°C for 1 h, at which point they were fixed and processed for immunofluorescence.
RESULTS

Scyl1
Interacts with COPI Coat Components-Scyl1 is composed of an N-terminal kinase-like domain and a C-terminal region containing three Huntingtin, elongation factor 3, PR65/A, TOR repeats and a coiled-coil domain (Fig. 1A) . To better understand the function of Scyl1, we searched for protein-binding partners using pull-down assays from brain extracts with GST-full-length Scyl1 or the isolated C-terminal region (Fig. 1A) . Specifically bound proteins were separated by SDS-PAGE followed by Coomassie Blue staining and tandem MS. As is common for relatively large GST fusion proteins, both GST-full-length and GST-C-terminal region fusion proteins had lower molecular weight bands corresponding to degradation products (supplemental Fig. 1 ). Despite this, a notable Scyl1-binding partner was detected at ϳ130 kDa with both constructs (supplemental Fig. 1, arrows) . Tandem MS of the bands led to 151 tandem MS profiles assigned to peptides with 92% of the peptides encoding ␣COP. ␣COP is one member of the heptameric COPI coat complex, which also includes ␤, ␤Ј, ␥, ␦, ⑀, and subunits (22) (23) (24) . An additional specific band was seen at ϳ110 kDa with the C-terminal construct (supplemental Fig. 1, arrowhead) . Tandem MS of this band revealed 98 assigned peptides nearly evenly distributed between four proteins, the ␣-and ␤2-adaptin subunits of the AP-2 complex, which is involved in CCV formation, as well as ␤COP and ␤ЈCOP. The identification of ␣-and ␤2-adaptin is consistent with the prior identification of Scyl1 in pull-downs using the ear domains of ␣-and ␤2-adaptin (10). The identification of ␣, ␤, and ␤ЈCOP subunits reveals that Scyl1 binds to components of COPI coats. Confirmation was obtained by ␤COP blots of Scyl1 pull-downs, which demonstrated that the interaction occurs with both the full-length protein and the isolated C-terminal region (Fig. 1B) . Immunoprecipitation of ␤COP from brain extracts led to a specific co-immunoprecipitation of Scyl1 ( Fig.   1C ), and endogenous ␤COP in HEK-293 cells co-immunoprecipitated with GFP-full-length Scyl1 transfected into the cells (data not shown). In contrast, we did not detect co-immunoprecipitation of Scyl1 and the AP-2 complex (supplemental Fig.  2, A and B) . Together, these data reveal Scyl1 as a specific COPIbinding partner.
Scyl1 Binds COPI Coats through a RKXX-COO
Ϫ Motif-We next sought to determine the binding site on Scyl1 for COPI coats. For type 1 integral membrane ER-resident proteins, a KKXX motif, where K is present at the Ϫ3 and Ϫ4 positions, is an efficient ER retrieval signal (15) . KKXX-COO Ϫ motifs bind the COPI coat complex to target ER proteins that have escaped from the ER into COPI vesicles for retrograde transport (13, 14) . Similar COPI-binding motifs are found in the p24 family of proteins, which constitutively cycle between the ER and the Golgi (15) . KKXX-COO Ϫ motifs have been variously shown to bind ␥COP (25) or the WD40 domains at the N terminus of ␣COP and ␤ЈCOP (26, 27) . However, a recent study indicates that whereas KKXX-COO Ϫ motifs from ER residents bind ␣ and ␤ЈCOP, p24 proteins may bind exclusively to ␥COP and that this depends on other determinants (28) . Interestingly, following the coiled-coil domain, Scyl1 contains a 10-amino-acid stretch that ends with the sequence RKLD-COO Ϫ ( Fig. 2A) . Deletion of the last 10 amino acids of Scyl1 greatly reduces but 
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does not eliminate its binding to COPI coats, as indicated with an antibody against ␤COP (Fig. 2B) . Mutation of RK to AA ( Fig.  2A) leads to a similar decrease in binding (Fig. 2B) . The residual binding seen with these constructs is eliminated upon subsequent deletion of the coiled-coil domain of Scyl1 (Fig. 2, A and  C) . Thus, Scyl1 primarily uses a sequence similar to the canonical motifs found in ER-resident and p24 proteins for binding to COPI coat proteins with a probable second COPI-binding site in the coiled-coil domain.
To compare the COPI binding properties of the RKLD-COO Ϫ sequence with a KKXX-COO Ϫ motif, we prepared a GST fusion protein encoding the last 15 amino acids of p24␣2 ending with KKLV-COO Ϫ , which was previously shown to bind COPI coats (15) . GST-p24␣2 binds COPI, as indicated by ␤COP Western blot, but there is less binding than to GSTScyl1, although there is less Scyl1 fusion protein in the assay (supplemental Fig. 3A ). To examine this further, we performed binding assays over a range of fusion protein concentrations from 425 to 6800 nM for GST-p24␣2 and 12.5-200 nM for GSTScyl1. ␤COP binding to Scyl1 saturates at ϳ100 nM fusion protein with half-maximal binding at ϳ50 nM (supplemental Fig.  3B ). In contrast, binding to p24␣2 does not saturate under these conditions, and the half-maximal binding is greater than 3.4 M (supplemental Fig. 3B ). Thus, Scyl1 appears to have higher affinity than p24␣2 for COPI coats. To examine whether the two motifs bind to the same or different sites on COPI coats, we performed peptide competition experiments in which GSTScyl1 was incubated with brain extracts in the presence of increasing amounts of a peptide encoding the 16 C-terminal most residues of Scyl1 including RKLD-COO Ϫ , the 15 C-terminal most residues of p24␣2 including KKLV-COO Ϫ , or an epsin peptide encoding DPW motifs and previously shown to compete binding of DPW proteins to the ␣-ear of AP-2 (29) . Binding of COPI coats was monitored by ␤COP Western blot. Although the Scyl1 peptide competed binding of GST-Scyl1 to COPI coats, neither the epsin peptide nor the p24␣2 peptide had any effect (Fig. 2D) . However, both the p24␣2 and the Scyl1 peptides competed binding of COPI coats to GST-p24␣2, whereas the epsin peptide had no influence (supplemental Fig.   FIGURE 2 . Identification of the COPI-binding site in Scyl1. A, schematic representation of Scyl1 constructs used in pull-down experiments. Fulllength (FL), Scyl1 lacking the last 10 amino acids (⌬10), full-length with an RK 3 AA mutation (FL (RK-AA)), and Scyl1 lacking the coiled-coil domain and the last 10 amino acids (⌬coil). HEAT, Huntingtin, elongation factor 3, PR65/A, TOR. B and C, constructs in A, fused to GST, were coupled to glutathioneSepharose and incubated with a rat brain extract, and specifically bound proteins were processed for Western blot with antibodies for the indicated proteins. Starting material (SM) represents 1 ⁄20 of the input. D, equal aliquots of GST-FL-Scyl1, prebound to glutathione-Sepharose, were incubated with rat brain extract in the presence of increasing concentrations of peptides encoding a region of epsin containing two DPW motifs (epsin peptide), the 16 C-terminal most residues of Scyl1 including RKLD-COO Ϫ (Scyl1 peptide), or the 15 C-terminal most residues of p24␣2 including the sequence KKLV-COO Ϫ (p24␣2 peptide). The amount of GST-Scyl1 present in each pull-down is revealed by Ponceau staining, and the molar ratio of peptide to GST fusion protein is indicated. Specifically bound proteins were processed for Western blot with ␤COP antibody. 3C). One possible explanation for these data is that the RKLD-COO Ϫ of Scyl1 binds to a distinct site on COPI coats when compared with the KKLV-COO Ϫ sequence of p24␣2. However, since Scyl1 binding is of higher affinity, and the peptide sequences are related, the Scyl1 peptide is able to compete binding of p24␣2 to its unique site in COPI coats. It is also possible that Scyl1 has two binding sites on COPI coats, one of higher affinity that is unique from that of p24␣2 and a second that is identical to that of canonical KKXX-COO Ϫ motifs. Further studies will be required to distinguish between these two related hypotheses and to determine the precise binding subunit and site on COPI coats.
Scyl1 Co-localizes with ␤COP-We next examined the localization of Scyl1 by immunocytochemistry. Confocal immunofluorescence analysis in COS-7 and HeLa cells revealed endogenous Scyl1 staining in peripheral punctae and punctae that were concentrated in a juxtanuclear area. A representative example in HeLa cells is shown in Fig. 3A . Both the peripheral and the juxtanuclear pools of Scyl1 co-localize with ␤COP (Fig. 3A) . Three independent pieces of data strongly support that the staining is specific and due to endogenous Scyl1. First, GFP-tagged full-length Scyl1 co-localizes with ␤COP at both peripheral punctae (Fig. 3B ) and in the juxtanuclear area (see Fig. 6 ). Similar results are seen for a GFP-C-terminal Scyl1 construct (Fig. 3B and data not shown). Second, as determined by Western blot, two siRNA sequences targeted against Scyl1 lead to a dramatic and specific reduction in Scyl1 expression in HeLa cells when compared with a control siRNA (Fig. 4A) , and both siRNAs lead to a drastic reduction in immunofluorescence signal with the Scyl1 antibody (Fig. 4B) . The loss of both the juxtanuclear and the peripheral punctate pools of endogenous Scyl1 is highlighted in cultures in which cells treated with control siRNA or Scyl1-specific siRNA were mixed prior to immunofluorescence analysis (Fig. 4C) . Lastly, the antibody used to detect endogenous Scyl1 in this study is the same as that used by Schmidt et al. (3) in which mdf mice suffering from loss of Scyl1 expression show little immunocytochemical signal. Although Scyl1 also binds to ␣-and ␤2-adaptin in pull-down assays (10), 4 it does not co-localize with AP-2 (supplemental Fig. 2B) . Thus, the Scyl1 staining detected here is specific and reveals that the protein is localized to COPI-coated membranes, consistent with its binding to COPI coat proteins.
The Juxtanuclear Pool of Scyl1 Is Localized to the cis-Golgi-COPI coats mediate membrane budding throughout the Golgi complex. Thus, the juxtanuclear pool of Scyl1 may correspond to membranes of the Golgi. To test this possibility, we first performed co-localization studies with protein markers of the cis-and medial-Golgi and the trans-Golgi network (TGN). Scyl1 co-localized in part with formiminotransferase cyclodeaminase (FTCD), also known as 58K, a cis-Golgi marker (30, 31) . A representative example is seen in Fig. 5A . Co-localization was limited to the juxtanuclear pool of Scyl1, and no co-localization of 58K/FTCD with the more peripheral Scyl1 punctae was observed (Fig. 5A) . In fact, these peripheral punctae co-localize with a marker of the ERGIC (see Fig. 7 ). Little or no co-localization of Scyl1 was seen with AP-1 (supplemental Fig. 4) . The major pool of AP-1 is localized to the TGN, but AP-1 is also found on endosomes, indicating that there is little Scyl1 at either location. There was limited co-localization of Scyl1 with the medial Golgi protein mannosidase II (supplemental Fig. 4) . Together, these data suggest that the juxtanuclear pool of Scyl1 is localized to the Golgi and is predominantly at the cis face.
To further explore the Golgi localization of Scyl1 and to more objectively determine the relative localization of the protein within the Golgi stack, we examined the influence of nocodazole on its distribution. Nocodazole is a microtubule-depolymerizing agent that causes the Golgi apparatus to disassemble by inhibiting the microtubule-dependant anterograde flux of Golgi-resident proteins from ER exit sites, resulting in the formation of numerous polarized Golgi ministacks (30, 32, 33) . Golgi ministacks are useful in determining the localization of a protein within the Golgi stack because of the simplified geometry of Golgi elements. Following a 3-h treatment of HeLa cells with 33 M nocodazole, Scyl1 distributed to Golgi ministacks, where it partially co-localized with 58K/ FTCD and a second cis-Golgi marker, GM130 (34) (Fig. 5B) . In contrast, Scyl1 showed little co-localization with AP-1 in nocodazoletreated cells (Fig. 5B) . We next quantified the localization of GFPScyl1 relative to the cis-Golgi marker GM130 and the TGN marker TGN46 using large numbers of cells and a fully automated procedure that scores the intensity peak of an unknown protein relative to the intensity peaks of cis-and trans-Golgi markers in triply stained nocodazole-treated cells (35) . In this scoring system, the peak intensity of the unknown protein is positioned on a coordinate system in which 0 and 100 represent peak intensities corresponding to the cis or trans marker, respectively. A detailed description of the procedure is found in Dejgaard et al. (35) . Here, Scyl1 gave a mean score of 28.0, consistent with an early Golgi localization for the pool of the protein localized to Golgi ministacks (Fig. 5C) . As a control, mannosidase II, which is used as a medial Golgi marker in HeLa cells, gave a score of 50.4 (Fig. 5C) , consistent with our previous results (35) . Together, these data strongly support that the juxtanuclear FIGURE 6. Scyl1 co-localizes with ␤COP at the cis-Golgi. HeLa cells, transfected with GFP-Scyl1, were processed for immunofluorescence to reveal endogenous ␤COP (red) and 58K/FTCD (blue). The degree of colocalization of each pair is revealed in the merged images. The triple merge is the merge of all three channels, and the box in the triple merge is shown at higher magnification to the left. The arrows point to co-localizing structures. Bar, 10 m. pool of Scyl1 is localized predominantly to early Golgi elements. Interestingly, triple staining using GFP-Scyl1, a monoclonal antibody for ␤COP and a polyclonal antibody for 58K/FTCD, revealed overlap between the three proteins (Fig. 6) , further demonstrating that Scyl1 is localized to cis-Golgi membranes positive for COPI coat proteins.
The Peripheral Pool of Scyl1 Is Localized to the ERGIC-A second major site of COPI-mediated membrane budding is the ERGIC. We thus sought to determine whether a pool of Scyl1 was localized to the ERGIC using YFP-tagged ERGIC53, a marker of this compartment (33, 36) . YFP-ERGIC53 was seen predominantly in a juxtanuclear area with additional peripheral punctae. A representative example is shown in Fig. 7 . YFP-ERGIC53 co-localized with Scyl1 in the juxtanuclear area (Fig. 7) . By increasing the gain of the microscope, the peripherally distributed pool of YFP-ERGIC53 became more apparent and was seen to co-localize with Scyl1 (Fig. 7) . Thus, a pool of Scyl1 is localized to the ERGIC.
Scyl1 Redistributes to Golgi Remnants following BFA Treatment-We next examined the influence of the fungal toxin brefeldin A (BFA) on Scyl1 localization. BFA inhibits the function of Arf1, leading to a rapid loss of COPI coat proteins from Golgi membranes. Long term treatments (20 -30 min) cause redistribution of Golgi enzymes into the ER (33, 37) , whereas peripherally associated cis-Golgi proteins like GM130 and cycling proteins such as ERGIC53 remain in membranous structures, referred to as Golgi remnants, which are distributed throughout the cytosol (33, 38) . Following a 20-min BFA treatment, GM130 was seen to redistribute into Golgi remnants with a representative example shown in Fig.  8A . Under these conditions, the juxtanuclear Scyl1-positive puncta became more distributed, but Scyl1 remained punctate and co-localized with GM130 in Golgi remnants (Fig.  8A) . Similar results were seen for transfected GFP-Scyl1 (Fig. 8B ). In addition, Scyl1 is co-localized with YFP-ERGIC53, and YFP-ERGIC53 is co-localized with GM130 in the Golgi remnants (Fig. 8B) . Together, these data demonstrate that Scyl1 is localized to the ERGIC and cisGolgi in an Arf1-independent manner.
Scyl1 KD Disrupts COPI-mediated Retrograde Traffic of the KDELR-Retrograde transport of ER-resident proteins is accomplished through COPI-dependent mechanisms (39) . The interaction of Scyl1 with COPI proteins and its localization to COPI-positive membranes prompted us to examine whether the protein is involved in this pathway using a loss of function approach. We identified two siRNA sequences that lead to specific KD of Scyl1 (Fig. 4) . We thus used KD in conjunction with a VSVGts045-KDELR chimera to analyze for trafficking defects. Unlike transmembrane domain ER residents that use direct COPI binding to concentrate in COPI vesicles, soluble ER-resident proteins use C-terminal KDEL sequences to bind the KDELR, which mediates their COPI-dependent retrieval to the ER (40) . The VSVGts045-KDELR chimera cycles between the ER and the cis-Golgi at the permissive temperature of 32°C, but at the restrictive temperature of 40°C, receptor chimera that has undergone retrograde trafficking becomes trapped in the ER due to misfolding, providing a previously used assay (20, 21, 41) to examine COPI-dependent retrograde traffic. In HeLa cells transfected with control siRNA, the VSVGts045-KDELR shows its predicted steady-state juxtanuclear localization at the permissive temperature, which is lost at the restrictive temperature (Fig. 9A) . In contrast, the receptor is predominantly found in the juxtanuclear compartment of Scyl1 KD cells at both the permissive and the restrictive temperatures (Fig. 9A) . Quantification reveals a significant dif- ference (Student's t test, p Ͻ 0.01) in the number of cells containing Golgi localized VSVGts045-KDELR in control versus Scyl11 siRNA-treated cells (Fig. 9B) . Importantly, Scyl1 KD did not affect the anterograde traffic of VSVG from the ER to the TGN (supplemental Fig. 5) .
To further examine the retrograde trafficking defect, we utilized a previously created HeLa cell line stably expressing a VSVGts045-KDELR chimera containing a D195N substitution (VSVGts04-KDELRm). This protein undergoes Golgi to ER trafficking as the wild type but at a slower rate (20) . VSVGts045-KDELRm stable cells co-stained for Scyl1 and VSVG demonstrate partial co-localization at the cis-Golgi (Fig. 10A) . We next transfected the cells with an mRFP-miRNA expression vector encoding a control miRNA sequence or a miRNA sequence directed against Scyl1. The Scyl1-specific miRNA sequence corresponds to siRNA 1 described in Fig. 4 and is different from the siRNA 2 sequence used in Fig. 9 . A dramatic and specific decrease in Scyl1 signal was seen in RFP-positive cells transfected with the Scyl1 mRFP-miRNA vector (Fig. 10B) . Using this system, we assayed for retrograde trafficking of the VSVGts045-KDELRm. Cells transfected with the control vector efficiently trafficked VSVGts045-KDELRm as observed by a loss of the cis-Golgi pool at the restrictive temperature (40°C). In contrast, cells expressing the Scyl1-specific miRNA demonstrated a defect in retrograde trafficking as VSVGts045-KDELRm remained predominantly at the cis-Golgi at the restrictive temperature (Fig. 10C) . Quantification of the results confirmed a significant effect (Student's t test, p Ͻ 0.001) of Scyl1 KD on VSVGts04-KDELRm trafficking. These data are compatible with a role for Scyl1 in COPI-mediated retrograde trafficking.
DISCUSSION
Mutations in Scyl1 are responsible for mdf mice that model aspects of human neuromuscular atrophies and spinocerebellar ataxias, but the molecular pathways in which Scyl1 functions are unclear. Scyl1 has been indirectly implicated in several cellular processes including regulation of centrosome function and clathrin-mediated endocytosis (10 -12) . Here, we demonstrate that siRNA-mediated KD of Scyl1, which mimics the nonsense-mediated decay of Scyl1 mRNA in mdf mice, leads to defects in retrograde trafficking of the KDELR. Consistent with this functional role, Scyl1 binds to COPI coat components in pull-down assays and co-immunoprecipitates with ␤COP from tissue extracts. In addition, endogenous Scyl1 co-localizes with ␤COP at the ERGIC and the cis-Golgi, sites of COPI-mediated membrane budding. The immunofluorescence staining of endogenous Scyl1 seen with the antibody used in this study is specific as GFP-tagged constructs of Scyl1 reveal an identical pattern of ␤COP co-localization. Moreover, loss of Scyl1 expression as the result of a mutation in the mdf mouse (3) or through siRNA-mediated KD in cell lines eliminates endogenous Scyl1 staining. Taken together, these studies provide strong evidence that Scyl1 functions as an accessory protein to modulate COPI-mediated trafficking.
The formation of CCVs is regulated by a complex machinery composed of numerous accessory proteins (42, 43) . Given that the formation of CCVs and COPI-coated vesicles are mechanistically and evolutionarily related (44) , it is reasonable to envision that multiple accessory proteins exist to regulate COPIcoated vesicle formation and cargo selection. In fact, Scyl1 and its homologue, Scy1-like 2/CVAK104, which functions in CCV formation at the TGN (7), provide an additional parallel between the different coat systems. Although Scyl1 function in COPI trafficking is demonstrated here, it should be noted that The arrows point to co-localizing structures. Bar, 10 and 2 m for the low and high magnification images, respectively. B, HeLa cells were transfected either with GFP-Scyl1 or with YFP-ERGIC53 and were then treated with BFA for 20 min followed by co-staining for endogenous GM130 or Scyl1 (red) as indicated on the panels. The arrows point to co-localizing structures. Bar, 1 m. there are six Scyl1 splice variants expressed in human cells and that only three possess the C-terminal RKXX-COO Ϫ motif responsible for COPI binding. Since the peptide antibody used in this study is also directed against the C terminus, only fulllength Scyl1 was detected in this study, leaving open the possibility that C-terminally truncated splice variants of Scyl1 have other roles in the cell. Moreover, although Scyl1 does not colocalize or co-immunoprecipitate with AP-2, it does bind to the ␣-ear of the AP-2 complex (10), 4 and Scyl1 KD does lead to alterations in the clathrin-dependent entry of VSVG into cells (11) . Thus, it remains possible that Scyl1 has additional functions in clathrin-mediated endocytosis.
Scyl1 was not detected in a recent proteomics analysis of COPI-coated vesicles (45) . However, there are many examples in proteomics studies where peripheral membrane proteins clearly associated with a particular organelle are not identified by MS analysis of the compartment isolated by subcellular fractionation (see for example Ref. 17) . Alternatively, as an accessory protein for COPI vesicle traffic, Scyl1 may be associated with the compartments from which COPI coats bud, but not associated with the vesicles themselves, or it may be only transiently associated with the vesicles. For example, dynamin, synaptojanin, and other CCV accessory proteins are clearly involved in CCV formation, but they are not present on purified CCVs (17) . The exact function of Scyl1 in COPI trafficking is not currently known. However, given that it remains associated with membranes following BFA treatment, it is positioned to aid in the recruitment of COPI coat components to ERGIC/cis-Golgi membranes in cooperation with Arf1. Furthermore, given its kinase-like domain, Scyl1 may function to regulate the phosphorylation state of proteins involved in COPI budding or trafficking.
A well characterized mechanism for the selective retrieval of cargo via COPI vesicles involves dilysinebased sorting signals (46) , in which the C-terminal KKXX-COO Ϫ motif mediates the incorporation of ERresident transmembrane proteins into COPI vesicles via direct interactions with COPI subunits (15) . A variant of the KKXX-COO Ϫ motif, KXKXX-COO Ϫ , in which the lysines are found at the Ϫ3 and Ϫ5 positions, also sorts transmembrane cargo via direct interaction with COPI coats (27) . Intriguingly, Scyl1 ends in the sequence RKLD-COO Ϫ , and mutation of the RK to AA attenuates binding to ␤COP. Binding is eliminated with the additional deletion of the coiled-coil domain, which contains two dibasic sequences. It is tempting to speculate that these sequences contribute weakly to binding, and in fact, the peptide from the C terminus of Scyl1 completely competes GST-Scyl1 binding to COPI coats. Thus, Scyl1 uses KK-like motifs for binding to COPI. C-terminal dilysine motifs have been shown to function in COPI binding exclusively in the context of transmembrane proteins (24, 32) . Scyl1 has no putative transmembrane domains, there is a pool of the protein that is found in the cytosol following ultracentrifugation, and the microsome-associated pool of the protein strips from membranes with pH 11 (data not shown). Thus, Scyl1 provides a unique example wherein a C-terminal KK-like COPI-binding motif is operative in a cytoplasmic protein. It is, however, interesting to note that internal KK sequences have been shown to be involved in the binding of the cytosolic protein, regulator of G-protein signaling 4 to ␤ЈCOP (47) . This provides further support that the internal KK motifs within the helical domain of Scyl1 may contribute to COPI binding.
The precise site of binding for the Scyl1 RKXX-COO Ϫ motif is not known. The binding site for canonical KKXX-COO Ϫ motifs in transmembrane proteins has been variously assigned to ␥COP (25) or the WD40 domain of ␣COP (27) , and this may depend on whether the motif is found in p24 proteins or transmembrane ER residents (28) . The KXKXX-COO Ϫ motif binds exclusively to the WD40 domain of ␤ЈCOP (27) . Thus, even subtle variations in COPI-binding motifs can have dramatic effects on the nature of their interaction with COPI subunits. It is thus perhaps not surprising that the current data indicate that the RKXX-COO Ϫ motif in Scyl1 may utilize a different site on COPI coats than that used by the canonical motif, although they have overlapping binding properties. Another motif for COPI coat binding is the Arg-based motif (48) . Arg-based motifs conform to the consensus ⌽/⌿/RRXR (in which ⌽ and ⌿ indicate aromatic or bulky hydrophobic residues) (48) . Recently, the site for Arg-based motifs was identified as being composed of a 21-residue region of ␦COP and a 3-residue region in ␤COP (49). Thus, the Scyl1 RKXX-COO Ϫ motif joins the KKXX-COO Ϫ motif, the internal KK motif, and the Argbased motif as a new small motif for binding to COPI coats. This growing network of interaction motifs is again reminiscent of the CCV machinery in which a variety of small motifs including DP(F/W), FXDXF, WXXF-acidic, and FXXFXXL mediate the assembly of the endocytic machinery around AP-2 (50, 51) . Clearly, the relationship between the various COPI coat-binding motifs is complex and will require further study.
One of the central findings of our study is that a protein responsible for a neurodegenerative disease functions in the COPI trafficking pathway. Defects in proteins that function in vesicle trafficking have been linked to a variety of neurodegenerative disorders. For example, huntingtin-interacting protein 1, which was implicated in the pathophysiology of Huntington disease with its discovery as a binding partner for huntingtin (52) , is a CCV protein that regulates critical endocytic events in neurons (53, 54) . Hereditary spastic paraplegias are a clinically and genetically diverse group of disorders that are related to amyotrophic lateral sclerosis and are characterized by progressive and generally severe degeneration of upper motor neurons (55) . Thus far, 33 hereditary spastic paraplegia loci have been identified, leading to 16 disease genes (56) , and intriguingly, several of the disease gene products contribute to vesicle trafficking (57) . For example, spartin (SPG20) has been linked to clathrin-mediated endocytosis (58) , and spastin (SPG4) and ZFYVE27 (SPG33) localize to endosomes and are thought to function in intracellular trafficking (59 -61) . Perhaps most relevant to this study is the transmembrane GTPase atlastin 1 (SPG3A), which is localized to the cis-Golgi and the ERGIC (62) (63) (64) . Interestingly, expression of atlastin 1 with various disease mutations disrupts either vesicle budding at the ER or the transport of ER vesicles to the Golgi (62) and leads to alterations in ER morphology and Golgi structure (63, 64) . However, no studies have yet linked the COPI pathway to neurodegenerative disorders. Although COPI trafficking is fundamental to cellular function, and complete shutdown of the pathway results in cell death (65, 66) , modulation of regulatory proteins in the pathway likely compromises COPI trafficking to a point that still allows cellular survival. It is possible that certain cell types that place higher demands on the COPI trafficking machinery, for example, motor neurons where large amounts of protein and lipids are trafficked over long distances, may be more susceptible to death induced by a decrease in the functionality of the COPI pathway. Our study paves the way for further studies on a key regulatory component of COPI pathways and the role of these pathways in human disease.
